UPDATE: Morgan Stanley Reiterates Overweight Rating, Removes PT on Pfizer Following Investor Relations Lunch

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer PFE, but removed the $33.00 price target. In the report, Morgan Stanley noted, “We hosted Chuck Triano and Ryan Crowe from Pfizer Investor Relations for lunch in NYC on Thurs. Dec. 12. Discussions focused on Prevnar adult pneumonia prevention trial (CAPiTA), palbociclib breast cancer trial and potential early filing, and business segment reporting and potential breakup. CAPiTA data [is] imminent. The trial has concluded, and Pfizer is analyzing data and will disclose results in a press release in early '14. We assume 80% odds of success because Prevnar has decreased pneumococcal disease since it was introduced. The incremental sales opportunity from a positive CAPiTA could be $2 billion.” Pfizer closed on Thursday at $30.25.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsDavid RisingerMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!